These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3318089)

  • 61. Intravesical therapy in superficial bladder cancer.
    Witjes JA; Mulders PF; Debruyne FM
    Urology; 1994 Feb; 43(2 Suppl):2-5; discussion 6. PubMed ID: 8116130
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy.
    Cookson MS; Sarosdy MF
    J Urol; 1992 Sep; 148(3):797-801. PubMed ID: 1512829
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors.
    Lüftenegger W; Ackermann DK; Futterlieb A; Kraft R; Minder CE; Nadelhaft P; Studer UE
    J Urol; 1996 Feb; 155(2):483-7. PubMed ID: 8558641
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intravesical and intradermal Bacillus Calmette-Guérin application. A phase I study to the toxicity of a Dutch Bacillus Calmette-Guérin preparation in patients with superficial bladder cancer.
    Schreinemachers LM; van der Meijden AP; Wagenaar J; Steerenberg PA; Feitz WF; Groothuis DG; Tiesjema RH; de Jong WH; Debruyne FM; Ruitenberg EJ
    Eur Urol; 1988; 14(1):15-21. PubMed ID: 2963745
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T; Alter A; Wiechno P
    Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P; Holmäng S
    BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
    Eure GR; Cundiff MR; Schellhammer PF
    J Urol; 1992 Feb; 147(2):376-9. PubMed ID: 1732597
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences.
    Böhle A; Busemann E; Gerdes J; Ulmer AJ; Flad HD; Jocham D
    Dev Biol Stand; 1992; 77():199-209. PubMed ID: 1426663
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
    Robins DJ; Sui W; Matulay JT; Ghandour R; Anderson CB; DeCastro GJ; McKiernan JM
    Urology; 2017 May; 103():149-153. PubMed ID: 28163086
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
    Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
    Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical value of pathologic changes after intravesical BCG therapy of superficial bladder cancer.
    Bassi P; Milani C; Meneghini A; Garbeglio A; Aragona F; Zattoni F; Dalla Palma P; Rebuffi A; Pagano F
    Urology; 1992 Aug; 40(2):175-9. PubMed ID: 1502759
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S; Akaza H; Isaka S; Kanetake H; Kubota Y; Kuroda M; Shinohara N; Shinka T; Tachibana M; Naito S; Hirao Y;
    Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intravesical Bacillus Calmette-Guérin prophylactic treatment for superficial bladder tumors: results of a controlled prospective study.
    Melekos MD
    Urol Int; 1990; 45(3):137-41. PubMed ID: 2190405
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.
    Lamm DL; Thor DE; Harris SC; Reyna JA; Stogdill VD; Radwin HM
    J Urol; 1980 Jul; 124(1):38-40. PubMed ID: 6997513
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
    Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
    Soloway MS; Perry A
    J Urol; 1987 May; 137(5):871-3. PubMed ID: 3106653
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
    Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN
    J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Experience with bacillus Calmette-Guérin in patients with superficial bladder tumors. Value of monocyte activation in intravesical bacillus Calmette-Guérin therapy.
    Nissenkorn I; Lavie G; Keisari Y; Leib Z; Vilcovsky E; Servadio C; Shachter H
    Eur Urol; 1987; 13(4):246-50. PubMed ID: 2820737
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Peripheral blood lymphocyte response in patients with superficial transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guérin--a useful marker of response?
    Schmidt AC; Bouic PJ; Heyns CF; De Kock ML
    Br J Urol; 1993 Feb; 71(2):179-82. PubMed ID: 8461951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.